article thumbnail

Genetic tracing at the Huanan Seafood market further supports COVID animal origins

Science Daily: Pharmacology News

A new study provides a list of the wildlife species present at the market from which SARS-CoV-2, the virus responsible for the COVID-19 pandemic, most likely arose in late 2019. The study is based on a new analysis of metatranscriptomic data released by the Chinese Center for Disease Control and Prevention (CDC).

Marketing 324
article thumbnail

New tRNA tech aims to rewrite rare disease treatment

Drug Target Review

The landscape of genetic medicine is undergoing a profound transformation, driven by innovative approaches that challenge the traditional, disease-specific paradigms. My transition to biotech and rare diseases was deeply personal – my son was diagnosed with Duchenne muscular dystrophy in 2020. “My

Disease 80
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bristol Myers gets key FDA approval for bone marrow disease drug

BioPharma Drive: Drug Pricing

A broadened clearance for Reblozyl in myelodysplastic syndromes should help Bristol Myers offset the looming loss of revenue from top-selling medicines set to soon lose market exclusivity.

article thumbnail

BioMarin to buy rare disease drugmaker Inozyme for $270M

BioPharma Drive: Drug Pricing

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug.

Disease 161
article thumbnail

The Future of Generic Drug Development in Emerging Markets

Drug Patent Watch

The pharmaceutical industry is undergoing a significant shift, with emerging markets offering the next growth opportunity. This growth is driven by several factors, including the increasing prevalence of chronic diseases, cost-effectiveness, and patent expirations of branded drugs.

article thumbnail

Two former Alexion leaders fight through a tough market to sustain a rare disease biotech

BioPharma Drive: Drug Pricing

Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech's down market has made the company's journey difficult.

Marketing 130
article thumbnail

Same person, Different place: Twice the odds of a dementia diagnosis

Science Daily: Pharmacology News

With new medications on the market or in the works for Alzheimer's disease and other kinds of dementia, a new study suggests that getting the diagnosis needed to access these new treatments may depend on where you live.

Treatment 305